the 4 asymptomatic cases in which diagnosis was incidental, the most common symptom in these patients was diplopia, which occurred in 7 cases. The most frequently affected CN was the abducent nerve. In 4 patients, 1 of whom underwent resection and 3 of whom underwent biopsy before GKS, the diagnosis was based on histological findings. In the other 12 patients, the diagnosis was mainly based on MR images and clinical presentation. The MR images obtained in these patients showed intensely enhanced parasellar masses-iso-or hypointense on T1-weighted images and hyperintense on T2-weighted images. The characteristics of these patients are detailed in Table 1 .
Treatments were performed, with the aid of a local anesthetic agent, using a Leksell Gamma Knife model C (Elekta AB). Gadolinium-enhanced MR images of T1-weighted, T2-weighted, and FLAIR sequences were obtained for pretreatment localization. The mean peripheral radiation dose was 13.3 Gy (range 11-14 Gy) directed to the 40%-50% isodose line. The dose to the optic nerves was limited to less than 8 Gy.
Periodic follow-up was carried out for each patient. Both in-person interviews and MR imaging were undertaken to assess changes in patients' clinical symptoms as well as tumor volume. The MR images were imported to the workstation of the Leksell Gamma Plan (version 9.0, Elekta AB), where tumor volume was calculated. For a further description of the results, we classified tumor control into 4 grades based on the grading scheme of Wang et al. 22 Grade I was defined as an invisible tumor (disappeared); Grade II, a reduction in tumor volume that was ≥ 50% (significant shrinkage); Grade III, a reduction in tumor volume that was ≥ 20% but < 50% (partial shrinkage); and Grade IV, a reduction in tumor volume that was < 20% or an enlargement (no change). A rank sum test was used to assess the relationship between the grade of tumor control and radiation dose. The assessment of changes in clinical symptoms was based on results of the physical examination and patients' self-assessment. Obvious changes detected by physical examination or a patient assessment of > 50% improvement were classified as clinical improvement.
Results

Clinical Outcomes
The patients were followed up for an average time of 21.5 months (range 12-36 months). At the final follow-up examination, clinical improvement was reported in 11 of 12 patients with symptoms. The patient who had undergone resection previously reported unchanged ptosis and diplopia. The average interval between GKS and symptom improvement was 3.3 months (range 1-8 months). Except for a temporary headache, no newly developed neurological impairments were reported after GKS. The clinical outcomes of the patients are summarized in Table 1.
Radiological Outcomes
One year after GKS, Grade I or II tumor control was reported in 5 cases with an average reduction in tumor volume of 62.5% (range 55.0%-65.7%); Grade III or IV was reported in 11 cases. Among the 9 cases still participating in follow-up 24 months after GKS, there were 1 Grade I case, 7 Grade II cases, and 1 Grade III case. Tumor shrinkage (Grades I-III) was observed in 14 patients (87.5%) as of the last follow-up. The tumor control effect is detailed in Table 2 and Fig. 1 . Figures 2 and 3 show MR images in Cases 10 and 12, respectively.
The average peripheral dose of radiation in Grade I and II cases (11 patients) was 13.6 Gy, whereas the average dose in Grade III and IV cases (5 patients) was 12.6 Gy. The rank sum test showed a significant difference in radiation dose between Grade I-II and Grade III-IV cases (p = 0.008).
Discussion
Cavernous sinus hemangiomas comprise up to 3% of all cavernous sinus lesions and are more frequently observed in women whose ages are between the 4th and 6th decades. 10 Similar to findings in previous reports, 87.5% (14/16) of the patients in this cohort were female with a mean age of 42 years. The onset of CSHs is insidious. Clinical symptoms-including diplopia, ptosis, visual field defects, facial numbness, ocular pain, and headaches-are usually the results of gradual enlargement of the tumor. Cranial nerve VI was the most affected nerve both in previously reported series and in this cohort. 10, 19, 23 It may be because CN VI is found within the tumor, unlike CNs III, IV, or V, which usually stretch over the tumor surface. 10 However, these symptoms are not unique for CSHs. Other lesions arising within the cavernous sinus, such as meningioma, schwannoma, and pituitary adenoma, can cause similar clinical symptoms. For this reason, a high rate of preoperative misdiagnosis was reported before the widespread use of enhanced high-resolution MR imaging. 13 An asymmetrical, dumbbell-shaped lesion occupying the parasellar region and the middle cranial fossa may be discovered using CT or MR images. On CT scans, the adjacent bone structure appears normal or adsorbed, but carries no sign of the hyperplasia seen in meningiomas. 3 The characteristic appearance of CSH on MR images reported from the 1990s greatly helped the preoperative diagnosis. 8, 10, 12, 24 The tumors may appear iso-or hypointense on T1-weighted MR images and display a significantly homogeneous or heterogeneous enhancement in response to a gadolinium-DTPA injection. Usually, no edema reaction around the tumor can be observed. Welldefined tumor hyperintensivity on T2-weighted MR images and no "dural tail" signs on enhanced MR images can help distinguish CSHs from meningiomas. However, there are still some difficulties in distinguishing a diagnosis of CSH from those of other tumors of the cavernous sinus. The pulse sequence of FLAIR is an inversionrecovery technique that can nullify fluids on the image. The high CSF signal in T2-weighted and proton densityweighted images can be suppressed using the FLAIR sequence so that the pathological area adjacent to the CSF signal is seen more clearly. This technique has been widely used for the diagnosis for multiple sclerosis. 1 However, only limited information about imaging findings of CSHs using FLAIR is available. 20 Unlike other tumors arising from the cavernous sinus, all of the CSHs in our study exhibited hyperintensity on FLAIR images. The results indicate that the FLAIR sequence could be a useful tool for preoperative diagnosis of CSHs. The characteristics of MR images of CSHs are detailed in Table 3 .
Since CSHs are benign tumors, cure is possible if complete resection is achieved; however, debate still remains as to what is the optimum treatment strategy. Re- section is recommended as a primary treatment option by some centers. 15, 18, 25 Nevertheless, total resection of these tumors is a great challenge because of excessive intraoperative hemorrhage and the potential for injury to CNs due to the complicated neurovascular structures of the cavernous sinus. Although Zhou et al. 25 reported that total tumor removal was obtained in 12 of 13 patients by using the epidural approach, in most previous studies the total resection rate was only 30%-44% and there was a high rate of complications. 4, 15, 18, 25 In our study, severe blood loss was encountered in the 4 patients who had undergone open biopsy or partial resection. Because of the high risk of open surgery, noninvasive techniques should be considered for these patients. Since the first successfully treated case was reported by Iwai et al., 7 more reports on GKS for the treatment of CSHs have been published indicating a good response and low complication rate. 2, 6, 9, 14, 16, 19, 23 A recently published systematic review and meta-analysis, which included 59 cases with a mean follow-up period of 49.2 months (range 6-156 months), added to the eidence that GKS can be a suitable option for the treatment of CSHs. Among the patients included in that study, tumor shrinkage was observed in 55 patients (93.2%). Thirtyfive of the 46 symptomatic patients reported clinical improvement. Additional CN impairments were reported by only 1 patient. 22 Nevertheless, in most previous reports, GKS was used as adjuvant treatment after open surgery. The effects of GKS as a primary treatment have only been reported sporadically and include limited cases. The present report, to the best of our knowledge, is one of the largest series with the largest average tumor volume of 30.4 cm 3 (range 1.5-61.5 cm 3 ) at a single institution. In most cases in this study there were large tumors and the patients underwent GKS as a primary treatment, resulting in a good response. A review of previous reports is summarized in Table 4 .
Obtaining periodic MR images is necessary to assess tumor control and provide quantitative information on tumor volume. Using the image registration function of the Leksell Gamma Plan software, tumor shrinkage was observed in 13 cases (81.2%). Tumor shrinkage was most significant during the first 2 years after GKS. Similar results were reported by Yamamoto et al. 23 and Ivanov and colleagues. 6 Rapid tumor shrinkage in our study and in previous reports provides convincing evidence that CSHs are radiosensitive. 6, 7, 9, 14, 19, 23 Further studies concerning the optimum radiation dose and treatment strategy are still needed, however, especially for patients harboring large tumors. Based on our review of the literature and events in our study, a peripheral dose of 8-19 Gy was planned for CSHs, accounting for the volume of the tumors and distances from the optic pathways and adjacent brain tissues. Yamamoto et al. 23 suggested that the threshold level of a peripheral dose for tumor control is 10-12 Gy and that a dose of 14-15 Gy is sufficient to control the growth of CSHs. The statistical analysis in our study indicates that a higher peripheral dose might result in better tumor control. However, the higher peripheral dose was usually delivered to patients with a smaller tumor volume to avoid radiation-related toxicity. Although many cases of large tumors in this study exhibited tumor shrinkage (Grades I-III) without inducing obvious neurological impairments, hypofractionated SRS may still be an option for these cases to increase the dose of radiation without increasing the toxicity. 21 The rate of short-term and perpetual complications of GKS for CSHs is relatively low. Only 1 of 59 patients had additional trigeminal nerve disturbance in the systematic review by Wang et al. 22 None of our patients developed new GKS-related neurological impairments, except for the 1 case of temporary headache, which may have been related to fixation of the head-stabilization frame. The optic chiasm and nerve are more susceptible to injury from radiotherapy than other CNs. The maximum radiation dose of 10-12 Gy to the optic pathways is expected to lead to radiation-related optic nerve injuries in less than 2% of the patients. 11 Thus a maximum radiation dose of 10 Gy to the optic pathways would be safe 
* ↑ = hyperintense; ↓ = hypointense; → = isointense; -= not reported. † In 1 of 19 cases mixed hypointensity and hyperintensity was seen on T1-weighted images. ‡ In 2 cases there were no apparent enhancement changes on subsequent contrast-enhanced sequences.
for treatment. Accounting for possible system errors in the Gamma Knife unit and deviation of MR images, we limited the dose to the optic nerves to less than 8 Gy. 7 Given the high risk of excessive blood loss from open surgery or biopsy, no histological evidence was available for 12 patients in our study. Diagnosis was mainly dependent on typical MR imaging and CT presentation. Although CSHs have imaging characteristics that are different from other tumors, misdiagnosed cases might have been included. This is the limitation of our study.
Conclusions
Cavernous sinus hemangiomas can present a characteristic appearance on T1-and T2-weighted MR images and FLAIR sequences. Although histological evidence remains the "gold standard" for the diagnosis of CSHs, MR imaging may play an important role in the preoperative diagnosis of these lesions. Our study showed that most cases of CSHs, even those in which the tumors were large, respond well to GKS. The results of this study add evidence that GKS is a useful and safe therapeutic method for CSHs, both as a primary or adjuvant treatment. Further studies with long-term follow-up and larger numbers of cases are necessary to optimize treatment conditions and verify the benefit of this treatment. 
